CDH1 and ovarian carcinoma: While a larger cohort should be tested in a prospective study to assess the precise clinical relevance of E-cadherin expression in ovarian cancers, the results from this study indicate that E-cadherin may serve as a critical marker not only for prediction of the prognosis of OC patients yet also for selection of patients who are at high risk of suffering an unfavorable clinical outcome and thus require more aggressive therapeutic modalities.